FDA approves Viatris’ Gwyn Lo, a once-weekly low-dose estrogen contraceptive patch supported by positive Phase 3 Luminous trial efficacy and safety data.
Written By: Kalyani Boharapi,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Viatris has received U.S. Food and Drug Administration approval for Gwyn Lo (norelgestromin and ethinyl estradiol transdermal system), a once-weekly combined hormonal contraceptive (CHC) patch for the prevention of pregnancy in women with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for combined hormonal contraception. The approval introduces a new low-dose estrogen transdermal contraceptive option and was supported by positive Phase 3 efficacy and safety data.
The product delivers norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day over a seven-day wear period. Women apply one patch weekly for three consecutive weeks, followed by one patch-free week.
A Low-Dose Weekly Hormonal Contraceptive Option
Gwyn Lo is a multilayer matrix transdermal system that continuously delivers both a progestin and an estrogen through the skin, avoiding the need for daily oral dosing. The patch offers a reversible, non-invasive contraceptive option for women who prefer weekly administration while receiving a lower estrogen dose than traditional combined hormonal contraceptives.
The approval comes as unintended pregnancy continues to represent a major public health challenge in the United States. According to data cited by the company, approximately 41.6% of pregnancies in 2019 were unintended, while many women discontinue or switch contraceptive methods because of dissatisfaction, highlighting the need for additional contraceptive choices.
Phase 3 Luminous Trial
FDA approval was granted through the 505(b)(2) regulatory pathway based primarily on findings from the Phase 3 Luminous study (NCT05139121).
The primary efficacy endpoint was the Pearl Index, which measures the number of pregnancies per 100 woman-years among women aged 18 to 35 years in the efficacy-evaluable population. Gwyn Lo achieved a Pearl Index of 4.14 (95% confidence interval: 2.77–5.95), demonstrating contraceptive efficacy in the intended patient population.
The study also showed strong real-world patch performance. Among 39,790 patches used during the year-long trial, only 1.3% completely detached before scheduled replacement.
Cycle control improved progressively throughout treatment. Rates of unscheduled bleeding or spotting declined from 34.5% during Cycle 1 to 20.0% by Cycle 13, while the average duration decreased from 3.2 days to 2.4 days over the same period.
Supporting evidence from four Phase 1 studies further demonstrated consistent drug delivery across different application sites and during activities such as treadmill exercise, sauna exposure, whirlpool use, and cold-water immersion.
Safety Profile Consistent with Combined Hormonal Contraceptives
The most frequently reported adverse reactions, occurring in at least 2% of participants, included application-site irritation (4.8%), application-site erythema (3.7%), application-site pruritus (3.7%), intercycle bleeding (3.9%), heavy withdrawal bleeding (2.0%), and nausea (2.0%).
Gwyn Lo carries the boxed warning common to combined hormonal contraceptives. It is contraindicated in women over 35 years of age who smoke because of an increased risk of serious cardiovascular events. The product is also contraindicated in women with a BMI of 30 kg/m² or greater, where the risk of venous thromboembolism may be increased.
Commercial Launch Planned Later This Year
Philippe Martin, Chief Research and Development Officer at Viatris, said the approval expands contraceptive options for women seeking a discreet, reversible, once-weekly patch with a lower estrogen dose. He also noted that the clinical program demonstrated efficacy in women with a BMI between 25 and less than 30 kg/m² without imposing a BMI-based limitation within that approved population.
Viatris expects Gwyn Lo to become commercially available in the United States later this year and plans to provide additional launch details during its upcoming financial results call. The approval further strengthens the company’s women’s health portfolio while expanding access to long-acting, user-friendly contraceptive options.
Reference
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch – Jul 29, 2026
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.